These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 27147514)

  • 1. Pharmacokinetic Modeling and Dose Selection in a Randomized, Double-Blind, Placebo-Controlled Trial of a Human Recombinant Alkaline Phosphatase in Healthy Volunteers.
    Peters E; Heuberger JAAC; Tiessen R; van Elsas A; Masereeuw R; Arend J; Stevens J; Pickkers P
    Clin Pharmacokinet; 2016 Oct; 55(10):1227-1237. PubMed ID: 27147514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biodistribution and translational pharmacokinetic modeling of a human recombinant alkaline phosphatase.
    Peters E; Stevens J; Arend J; Guan Z; Raaben W; Laverman P; Elsas AV; Masereeuw R; Pickkers P
    Int J Pharm; 2015 Nov; 495(1):122-131. PubMed ID: 26325308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selection of dosing regimen with WST11 by Monte Carlo simulations, using PK data collected after single IV administration in healthy subjects and population PK modeling.
    Fabre MA; Fuseau E; Ficheux H
    J Pharm Sci; 2007 Dec; 96(12):3444-56. PubMed ID: 17854075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population Pharmacokinetic Modeling of JNJ-53718678, a Novel Fusion Inhibitor for the Treatment of Respiratory Syncytial Virus: Results from a Phase I, Double-Blind, Randomized, Placebo-Controlled First-in-Human Study in Healthy Adult Subjects.
    Huntjens DRH; Ouwerkerk-Mahadevan S; Brochot A; Rusch S; Stevens M; Verloes R
    Clin Pharmacokinet; 2017 Nov; 56(11):1331-1342. PubMed ID: 28238203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers.
    Vaughan D; Speed J; Medve R; Andrews JS
    Clin Ther; 2010 Jan; 32(1):146-60. PubMed ID: 20171420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia.
    Geisser P; Banké-Bochita J
    Arzneimittelforschung; 2010; 60(6a):362-72. PubMed ID: 20648928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part II. Population pharmacokinetic and pharmacodynamic modeling and simulation.
    Wiltshire HR; Kilpatrick GJ; Tilbrook GS; Borkett KM
    Anesth Analg; 2012 Aug; 115(2):284-96. PubMed ID: 22253270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study protocol for a multicentre randomised controlled trial: Safety, Tolerability, efficacy and quality of life Of a human recombinant alkaline Phosphatase in patients with sepsis-associated Acute Kidney Injury (STOP-AKI).
    Peters E; Mehta RL; Murray PT; Hummel J; Joannidis M; Kellum JA; Arend J; Pickkers P
    BMJ Open; 2016 Sep; 6(9):e012371. PubMed ID: 27678541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacology of DP-b99 in healthy volunteers: first administration to humans.
    Rosenberg G; Angel I; Kozak A
    Br J Clin Pharmacol; 2005 Jul; 60(1):7-16. PubMed ID: 15963088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics, pharmacodynamics, safety, tolerability, and mass balance of single and continuous intravenous infusion of SPT-07A in healthy volunteers.
    Wang W; Wang Y; Zhao W; Zhong J; Wang Y; Chen X
    Eur J Clin Pharmacol; 2020 Jun; 76(6):785-793. PubMed ID: 32147750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, potential efficacy, and pharmacokinetics of specific polyclonal immunoglobulin F(ab')₂ fragments against avian influenza A (H5N1) in healthy volunteers: a single-centre, randomised, double-blind, placebo-controlled, phase 1 study.
    Bal C; Herbreteau CH; Buchy P; Rith S; Zaid M; Kristanto W; Han V; Reynaud C; Granjard P; Lépine B; Durand C; Tambyah PA
    Lancet Infect Dis; 2015 Mar; 15(3):285-92. PubMed ID: 25662592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human recombinant alkaline phosphatase inhibits ex vivo platelet activation in humans.
    Tunjungputri RN; Peters E; van der Ven A; de Groot PG; de Mast Q; Pickkers P
    Thromb Haemost; 2016 Nov; 116(6):1111-1121. PubMed ID: 27656709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of a human recombinant alkaline phosphatase on renal hemodynamics, oxygenation and inflammation in two models of acute kidney injury.
    Peters E; Ergin B; Kandil A; Gurel-Gurevin E; van Elsas A; Masereeuw R; Pickkers P; Ince C
    Toxicol Appl Pharmacol; 2016 Dec; 313():88-96. PubMed ID: 27760303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alkaline phosphatase for treatment of sepsis-induced acute kidney injury: a prospective randomized double-blind placebo-controlled trial.
    Pickkers P; Heemskerk S; Schouten J; Laterre PF; Vincent JL; Beishuizen A; Jorens PG; Spapen H; Bulitta M; Peters WH; van der Hoeven JG
    Crit Care; 2012 Jan; 16(1):R14. PubMed ID: 22269279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and Tolerability of Obiltoxaximab: A Report of 5 Healthy Volunteer Studies.
    Nagy CF; Leach TS; Hoffman JH; Czech A; Carpenter SE; Guttendorf R
    Clin Ther; 2016 Sep; 38(9):2083-2097.e7. PubMed ID: 27568215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamics and safety of the novel selective progesterone receptor modulator vilaprisan: a double-blind, randomized, placebo-controlled phase 1 trial in healthy women.
    Schütt B; Kaiser A; Schultze-Mosgau MH; Seitz C; Bell D; Koch M; Rohde B
    Hum Reprod; 2016 Aug; 31(8):1703-12. PubMed ID: 27288475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and tolerability of high-dose ulinastatin after 2-hour intravenous infusion in adult healthy Chinese volunteers: A randomized, double-blind, placebo-controlled, ascending-dose study.
    Chen Q; Hu C; Liu Y; Liu Y; Wang W; Zheng H; Rong L; Jia J; Sun S; Yu C; Liu YM
    PLoS One; 2017; 12(5):e0177425. PubMed ID: 28493932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and concentration-effect analysis of intravenous RGD891, a platelet GPIIb/IIIa antagonist, using mixed-effects modeling (NONMEM).
    Zannikos PN; Rohatagi S; Jensen BK; DePhillips SL; Rhodes GR
    J Clin Pharmacol; 2000 Oct; 40(10):1129-40. PubMed ID: 11028252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
    Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.